Investor Calendar Invites You to the Provectus Biopharmaceuticals Fourth Quarter and Fiscal Year 2015 Earnings Conference Call and Webcast Live on Thursday, March 10, 2016

KNOXVILLE, TN / ACCESSWIRE / March 9, 2016 / Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) will host a conference call and live webcast to discuss the results of the fourth quarter and fiscal year 2015, to be held Thursday, March 10, 2016 at 4:00 PM Eastern Time.

To participate in this event, dial 877-407-4019 domestically, or 201-689-8337 internationally, approximately 5 to 10 minutes before the beginning of the call. Additionally, you can listen to the event onlineat www.investorcalendar.com/IC/CEPage.asp?ID=174725 as well as via the Provectus Biopharmaceuticals website (www.pvct.com).

If you are unable to participate during the live webcast, the event archive will be available at www.investorcalendar.com or www.pvct.com.

You may access the teleconference replay by dialing 877-660-6853 domestically or 201-612-7415 internationally, referencing conference ID # 13629346. The replay will be available beginning approximately 2 hours after the completion of the live event, ending at midnight Eastern on June 30, 2016.

About Provectus Biopharmaceuticals, Inc.

Provectus Biopharmaceuticals, Inc. specializes in developing oncology and dermatology therapies. PV-10, its novel investigational drug for cancer, is designed for injection into solid tumors (intralesional administration), thereby reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and cancers of the liver. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. PH-10, its topical investigational drug for dermatology, is undergoing clinical testing for psoriasis and atopic dermatitis. Provectus has completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis. Information about these and the Company’s other clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus, please visit the Company’s website at www.pvct.com or contact Porter, LeVay & Rose, Inc.

SOURCE: Investor Calendar

ReleaseID: 437664